Hello, and welcome back to the Bell Potter Healthcare Conference. Following on from both PYC and Neuren, we are going to keep the rare disease theme going with our next presentation today from Alterity Therapeutics. Joining us for the presentation is the CEO and Managing Director, Dr. David Stamler. David, thanks for joining us today. I will do a quick introduction before we go through some slides. Alterity is a clinical-stage company developing its novel drug candidate for a condition called multiple system atrophy, or MSA. Last year, Alterity achieved a major milestone with the completion of its phase II trial in MSA. Results showed Alterity's drug led to significantly slower rates of decline across various symptoms in what is a fast-progressing condition. As always, attention now focuses on what is next for Alterity as the company goes through the different preparations needed before starting its phase III clinical trial.
With that introduction, David, thanks again. I will pass it over to you for some slides, and then we will do some Q&A afterwards.
Great. Well, good afternoon, everyone, and thanks for attending. I am really happy to be able to give you an update on the progress we have made in the recent past on our lead program. These are our forward-looking statements, which I would encourage everyone to review regarding risk of investing. Alterity is actually a word in the English language that means the state of being different, and we think this is an important way to embody what we try and do with our therapies. We are trying to change the state of individuals with these neurodegenerative diseases from disease to health. And in doing so, we are really trying to slow the course of disease progression with our therapies.
To just give you an overview of our program and the recent progress that we have made, as Thomas mentioned, last year we disclosed exceptional phase II data for our lead indication, demonstrating a slowing of disease progression on a clinical endpoint that the FDA and other regulatory authorities recognized to support a drug approval. And on that endpoint, we showed upwards of 50% disease slowing compared to placebo with a favorable safety profile. MSA is, that I will tell you more about in a moment, is a rare disease that affects up to 50,000 patients in the United States, a nd because there is nothing approved to treat this devastating condition, the estimated peak sales are around $2.4 billion annually. We have a differentiated profile by offering an oral therapy that targets an upstream source of pathology that really drives the disease pathology and progression.
Importantly, on item four on this slide, you will see that we have had excellent interactions with the FDA this year, culminating in a very successful End-of-Phase II meeting where we obtained alignment on the design for the phase III program. In addition to myself, several other team members have all contributed to drug approvals on CNS products through the FDA. Multiple system atrophy, or MSA, it is a Parkinsonian disorder, which means early on it can look like Parkinson's disease. However, the other side of the coin, as Thomas hinted at, is that the disease progresses very rapidly, more like ALS. It can be a bit of a misnomer to view it as a Parkinsonian disorder. It is not just an aggressive form of Parkinson's disease. It is a distinct entity that can have devastating effects on individuals.
You see that pictured on the right side of the slide, where patients can present with non-specific symptoms like urinary problems or low blood pressure when they stand up, but this rapidly progresses to abnormal movements, the Parkinsonism that we have probably seen in friends or family members, cerebellar dysfunction, which leads to unsteady gait and frequent falls. Then patients often do progress to require a walking aid like a cane or a walker within just a few years. Unfortunately, more than 50% of patients require wheelchair assistance just within five years of symptom onset, and the median survival is just about seven and a half years. So there truly is an urgent need to find new therapies for this disease.
I will tell you about how our drug targets the disease, and in a way, we do this by targeting the excess iron that accumulates in the areas of pathology. This is seen on the left side of the slide, which comes from an autopsy study that looked at the brains of patients who died from MSA. The patients are in blue, the controls of the same age are in gray, and what we see is that the patients have elevated levels of iron in these five regions that are listed, and these are the regions of the brain where we have the pathology that leads to neuron death and dysfunction. So what we are really trying to do with our therapy is to mitigate the damage of this iron and try and prevent its contributions to the pathology.
On the right side of the slide, you see how that iron actually drives the pathology. You have this so-called reactive iron in the green that generates free radicals that damage intracellular structures like mitochondria and DNA, that iron itself causes a very important protein in the central nervous system called alpha-synuclein to aggregate, and in that way, it cannot function. Then these different factors interact with one another, and it kind of leads to this vicious cycle of pathology that ultimately leads to progressive nerve loss that underlies the dysfunction. So what we are trying to do with our therapy is to really break this cycle, reduce the amount of that reactive iron, and to slow down the pathologic process. How do we do that? We do that with our molecule called ATH434.
This is a small molecule drug candidate, which means it can be orally administered and absorbed, which is very convenient for patients and physicians. I've described the fact that we bind iron, but we bind and redistribute the iron within the central nervous system, or the CNS. We don't actually bind it and remove it from the body, so this is a much safer approach. The drug, in addition to having potential to treat multiple system atrophy, also can treat Parkinson's disease and Friedreich's ataxia. At least in animal models, we've shown very nice efficacy in Parkinson's disease. This remains an important secondary indication for us to consider.
From a regulatory standpoint, based on the small number of patients, we do have orphan drug designation in the U.S. and in the E.U., and we do have fast track designation in the U.S., which is really based on the potential for this drug, as has been shown in animal models and clinical studies, to really address this unmet need. This is the design of the phase II study that Thomas referred to at the outset. This is the gold standard design for a clinical trial.
It's a double-blind, placebo-controlled, randomized study where we enrolled a total of 77 patients who met clinical criteria for MSA, and they were required to have elevated brain iron on MRI and elevated levels of a plasma protein called NfL, and that's a protein that's elevated in MSA but not in Parkinson's disease, because we want to make sure that if we recruit early patients, that they don't actually have Parkinson's disease. Patients are then randomized in equal numbers to the 75 milligram or 50 milligram dose group or matching placebo, treated for 12 months, and then we looked at these endpoints that are listed on the right side of the slide.
The most important one is this MSA rating scale that I mentioned at the beginning, and that is the endpoint that assesses multiple areas of dysfunction in MSA that are shown on the bottom part of the slide now. These represent the 12 or so domains that are typically affected in patients with MSA, anything from speech or swallowing, fine motor skills, leading to the ability to cut food, feed themselves, dress, et cetera. This endpoint is the most important one, as mentioned, is the one that the FDA and other authorities look to to support a drug approval. This is that MSA rating scale pictured. Now, it's a rather busy slide, but we see that the score on the scale is plotted on the y-axis, higher scores being worse.
We see that over the course of 12 months of treatment, placebo-treated patients in gray worsened or had an increase in their score by about eight points, whereas over the same period of time, the two active treatments, 50 mg and 75 mg in blue and green, had anywhere from 34%-46% less decline than the placebo-treated patients, and that is equivalent to a treatment effect of 2.7 points-3.7 points. What is important is that both doses exceed the minimally clinically important difference of 1.5 points that has been shown independently. The other issue, just to mention, is some question why the effect at 75 mg was lower. We did see baseline differences in disease severity in the 75 mg dose group that predisposed them to rapid progression, which largely explains this difference.
We have also done extensive population PK studies in the phase II study, which demonstrated that we had a saturation of effect at the 50 mg dose group, and that there was no benefit from going higher. These are two other very important endpoints that we assessed in the study, and these are referred to as patient-reported outcomes, where the patient is handed a questionnaire at baseline, and then they fill out the questionnaire, and then repeat that assessment every three months during the course of the study.
On the left, this assesses the swallowing impairment that is typical in MSA patients, and what we see is over the course of 52 weeks, that the placebo patients worsen or have an increase in scores by about nine points, whereas the active treatments decline by significantly less than that, with the effect at the 50 mg dose group being statistically significant. Similarly, the Orthostatic Hypotension Symptom Assessment, this is the low blood pressure that patients experience and the lightheadedness that goes along with that when they go from a sitting to a standing position. Again, the scores on this scale clearly deteriorated in the placebo patients by increasing by about six points, whereas they stabilized in the two active treatment groups. What is important is both these symptoms are very impactful on people's day-to-day functioning.
The question is target engagement, and I think I mentioned that our drug targets and redistributes the excess iron that drives the pathology. What you see on this slide is the correlation between iron accumulation in the brains of patients who are treated with placebo and how that actually relates to their clinical worsening. What we see are very strong correlations, as noted by the height of the bar in the placebo patients, which mean that as the iron accumulates in the cells of these patients, it really does drive the pathology.
However, when you look at the patients who are receiving active treatment, as indicated in the blue and the green bars, this shows that the iron accumulation that may be occurring is not driving disease progression because it is being redistributed within the cells, so that it does not cause the harm that it does in the placebo patients. I mentioned at the beginning that we have had successful interactions with the FDA over the course of the year, and we did have our End-of-Phase II meeting in June, where we reached agreement with the FDA on the key elements of our phase III program. Number one, the selection and scoring of the UMSARS score, that is the MSA rating scale I showed you. They agreed with the study population of about 200 patients who had clinical and biomarker evidence of MSA.
They did agree with our plan to study the 50 milligram dose group and treat patients for 12 months. They also accepted many of the secondary endpoints that we proposed, including the two that I just showed you, the Swallowing Disturbance Questionnaire and the Orthostatic Hypotension Symptom Assessment. We agreed on statistical methods, quite important, that can affect how we measure the efficacy in the study patients in phase III. Finally, and importantly, they did agree with our plan to study patients in a single adequate and well-controlled pivotal trial, plus confirmatory evidence that should come from our phase II study. From a commercial standpoint, we commissioned an independent assessment from a group that conducted surveys in 100 U.S. neurologists. Half of them were generalists, half were specialists who treat MSA.
Based on those interviews and relatively conservative assumptions regarding patient prevalence of around 19,000 patients at peak, we estimate global peak sales to be $2.4 billion. The physician survey had a very high plan to prescribe the drug, with more than 70% being extremely likely or very likely to prescribe based on its profile. The drivers of physician interest were really the slowing of disease progression that I showed you on that MSA rating scale, as well as the stabilization of the orthostatic hypotension symptoms, because those are all very important contributors to impaired quality of life. To sum up, we are really positioned for success, having had our successful FDA interaction regarding our phase III design. We have had other meetings earlier in the year where we aligned on our plans for the non-clinical elements and the chemistry and manufacturing.
Regarding phase III readiness, we continue to analyze our data, and I think have really come up with a very sleek phase III study design, where we are very confident that we can recruit patients that are similar to our phase II population, and we expect we will have a robust response to treatment. We have done all the things that are necessary to really get ready to begin that phase III study by identifying sites, manufacturing drug, and we have demonstrated that we are initiating those clinical trial activities already. From a value standpoint, in August, we disclosed that we had a new U.S. composition of matter patent granted, which provides protection out to 2045, which really gives us the opportunity to pursue other important indications like Parkinson's disease. With that, I will conclude, and I will be happy to take the questions that Thomas may have for me.
Yeah. Thank you very much, David, for that run-through. I want to start with a slide you had towards the back end there, about the commercial opportunity and the number of patients that are out there in the U.S. I mean, we are talking rare diseases here, but it is not that rare. I think you said about 19,000 Americans that are assumed to be out there. The question for you is, how are MSA patients actually diagnosed, either for the trial, but then also in real-world clinical practice?
Yeah. It is a good question because it is not an easy diagnosis to make. As happens with these disorders, typically, if patients present with Parkinson's-like symptoms, people assume that they have Parkinson's disease, and they may actually respond initially to those treatments. But it is typical if they have more severe blood pressure problems or if they have significant bladder issues and urination problems, that the astute clinician might think, "This does not look like garden-variety Parkinson's disease." Oftentimes, it takes patients several years and several physicians to actually make that diagnosis. I think part of the issue is, with no available therapy, the education has probably lagged. Movement disorder neurologists know this, general neurologists generally not. I think the good news is with an approved therapy will come more patient education, earlier diagnosis, and hopefully earlier treatment, which will really kind of forestall the progression of disease.
Yeah, I think it is a totally fair point. This is the third rare disease company we have heard present in a row now, and I think there has been a consistent theme that when you are the first approved treatment, the reason or the motivation to get a diagnosis is not really there. But once you have a product approved, then for these specific rare conditions, that really is what drives the diagnosis rates to increase.
It is true. MSA, if anyone were to just go online, Google MSA, it is characterized as a devastating, fatal disease. Clinicians are reluctant to give that diagnosis early on unless they have something to offer a patient because it is, in effect, perceived as a death sentence, even though the course is variable. Yeah, I think getting an available therapy will make a big difference.
Yeah, great. We heard from Neuren, it was a really interesting example where he said, "Look, in our first drug, we partnered in a commercial," Acadia, in that case, did the phase III, but we kind of saw that and thought, "Hmm, maybe that is something we could do ourselves." Now with their second asset, they're prosecuting it. Your phase III trial in size is not that dissimilar, about 200 patients. How feasible do you think it is for Alterity to prosecute this phase III? I would presume pretty manageable.
Yeah, I think it is quite manageable. We've got a really seasoned team. I've directed many trials. Our head of clinical operations has run many phase III trials. It's very feasible for us to manage the trial on our own. Now obviously, if a partner becomes involved, they may be involved in trial oversight or may be involved in design decisions. But it's not unusual for small companies like us to be able to run a trial of this size.
Yes. Yeah, great. Okay. You've had plenty of interactions with the FDA, getting alignment on what that trial's going to look like. What, if anything, still remains to be done before you can start activating sites and get that trial up and running?
Yeah. I think we've manufactured the drug, both the drug substance, the powder, as well as the tablets. That still needs to be packaged and then released to the sites. We're still going through the site qualification process and identification process. Not every country starts at the same time, but we're focusing on a few key countries and trying to identify the sites. Believe it or not, the setup always takes more time than you'd like it to take. You've got to recruit. I was in a meeting where-
Yeah
Hearing from our operations group, we probably have about 12 vendors to 15 vendors involved in running the studies. Those groups need to be identified, contracted with, and then the heavy work starts. We are doing everything we can to really get ready for phase III. It is kind of lining up all the operations, finishing the drug packaging, et cetera.
Yeah, there is definitely a lot of aspects that need to align that you would not immediately think of. Let us talk about the actual results of this phase III trial. It will obviously live and die by the primary endpoint. How similar is the primary endpoint and the timing, duration that you are using in the phase III compared to what you have evaluated and reported in the phase II trial?
Yeah, that is a really good question. The endpoint is the same. The patient population that we are identifying is very similar to what we have done in phase II. The one difference, if you look at our corporate slide deck, is whereas we use brain iron to identify patients in phase II, we are going to use brain volume on MRI. We have shown that there is very good correlation between brain iron and brain volume, and it is much easier to operationalize. We are confident that we are going to get a very similar patient population, and using the criteria to define volume, I am very confident that we are going to be able to demonstrate efficacy in that patient population.
The other thing, it is probably worth mentioning, especially just in the heels of some negative news that has come out regarding an Alzheimer's program and some recent phase III studies that have failed in the Australian biotech industry. One of the things that I get asked about a lot is, what is the probability of success in phase III and how do you de-risk that? I think because the population is so similar to who we enrolled in phase II, because we are using the same endpoint, because the scale of our phase III study is only modestly larger than the phase II, it is only about two to 2.5 times the size, we can still use this very careful patient selection approach and de-risk that. We are confident about our probability of success in phase III.
Yeah. In this indication, MSA, there's no product approved at the moment, right? It was an interesting update, I think, from one of the peers in the space in MSA that had a trial reported recently, wasn't the outcome they wanted, seemed to result in a positive share price reaction for Alterity. Maybe any takeaways from you as to how that or the competitive landscape is developing?
Yeah. I continue to think that we're very well positioned regarding the competitive landscape. The compound that you mentioned was a very large phase II study. It was a 400-patient phase II study, and it was an interim analysis that led to futility. They felt that they could not succeed if they had completed the trial. Another trial that's ongoing that's in phase III is of similar size, maybe up 350 patients to 400 patients as well.
Okay.
I think doing large studies in MSA is a mistake. I've seen this. There's a company called Biohaven that did a development program several years ago, also a very large study, and I think people believe that by doing large studies, that you can have good power to demonstrate small treatment effects. I think in this disease, because large number of patients typically leads to either patients who are too far advanced or patients who are, if they're early, may not actually have the disease. I think big programs like that are really at risk for failure, which is why we've taken a much more careful approach so that we can carefully identify these patients and maximize the chance of success.
Yeah. Great. Just want to touch on IP quickly. This product you've been developing has been in preclinical and clinical development for a few years now, but you did recently announce some new composition of matter IP. Really interesting. How were you able to get that new composition patent IP, and is it fully granted and all finalized and owned by you now?
Yeah. So, good question. So, typically, the first patent on a drug, the first composition of matter patent is, if you will, the chemical structure, so kind of how it is written on the page in two dimensions. Whereas this patent, which is for the crystalline structure, is really the three-dimensional structure where the crystals form certain angles, and those are unpredictable and novel. Typically, patents like that are granted later in the life cycle of a compound. So, we identified that and were able to get that patent filed and granted. It is granted in the U.S. It is undergoing prosecution in other jurisdictions, but in the U.S., that patent has been granted. As mentioned, that is going to really open up, probably increase the opportunity in MSA, but also give us the opportunity to pursue development in major CNS indications.
Well, yeah, that is a really interesting point because in MSA, you obviously get orphan exclusivity for a few years regardless of the patent, but if you were to go into Parkinson's disease, you do not have that orphan exclusivity, so you would much more rely on that IP protection. Is Parkinson's disease still on the radar? When could we expect, if any, updates, or is it just kind of full focus on MSA, and see how the results go, then potentially Parkinson's disease?
Yeah, I think it is really the latter. We remain really interested in Parkinson's disease. I think I mentioned when I first came, we had an abundance of data in animal models of Parkinson's disease. There is similar pathology between MSA and Parkinson's disease if you look at slices of tissue under the microscope. Iron accumulates the same abnormal protein, alpha-synuclein aggregates. There is a lot of crossover, but I think considering the value that we would generate in MSA, the goal is get to MSA first and then pursue Parkinson's disease. A partner may come along that we have got various partner discussions going on, and resources from a pharma partner would make a big deal, both human resources and financial resources to pursue both programs in parallel.
Yeah, makes total sense. All right, final one before we finish up, David. Where is the financial profile of the company at in terms of your development ambitions?
Yeah. We last disclosed in our 4C that we had a little over AUD 40 million on the books. We are in a good cash position. We will need to either raise capital through a financing or through partnership, and we have been pursuing that dual track for some time. These things sometimes take longer than you want, but we still have very significant interest that we are pursuing. I think before we really get active and enrolling in phase III, we will have line of sight on that funding from one of those two channels.
Yeah, makes sense. All right, David, we are going to have to wrap it up there. Thank you once again for presenting to the conference today. Exciting times with your phase III getting started in the not-too-distant future.
Great. Thank you, Thomas.
All right, we are going to go to a quick lunch break. We will be back at about 1:00 P.M. for our afternoon session for the conference. We will see you then. Bye.